Related Experiment Video
Updated: Jun 10, 2026
08:15
Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway
Published on: May 10, 2024
Antidiabetic effect of Raphanus sativus root juice
Surekha Shukla1, Sanjukta Chatterji, Shikha Mehta
1Alternative Therapeutics Unit, Drug Development Division, Medicinal Research Lab, Department of Chemistry, University of Allahabad, Allahabad, India.
Pharmaceutical Biology
|August 7, 2010
Summary
Raphanus sativus root juice shows significant hypoglycemic and antidiabetic effects. This natural remedy effectively lowers blood glucose levels in various diabetic models, offering a promising oral treatment option.
Area of Science:
- Phytochemistry and Pharmacology
- Natural Product Research
- Diabetes Mellitus Therapeutics
Background:
- Extensive research explores medicinal plants for diabetes treatment.
- Developing novel oral antidiabetic agents with minimal side effects is a priority.
Purpose of the Study:
- To evaluate the glycemic attributes of Raphanus sativus (radish) root juice.
- To assess its potential as an oral antidiabetic agent in normal and diabetic rat models.
Main Methods:
- Oral administration of Raphanus sativus root juice at varying doses (100-400 mg/kg) to rats.
- Induction of diabetes using streptozotocin (STZ) in sub- and mild-diabetic models.
- Comparison with glibenclamide as a reference drug.
Main Results:
- The optimal dose of 300 mg/kg significantly reduced fasting blood glucose by 33.4% in normal rats.
- Glucose tolerance tests showed reductions of 15.9% in normal rats and 23.8-28.3% in diabetic rats.
- Raphanus sativus demonstrated dose-dependent hypoglycemic and antidiabetic effects.
Conclusions:
- Raphanus sativus root juice exhibits significant hypoglycemic potential.
- The findings support its efficacy as a natural antidiabetic agent.
- Further research may lead to novel oral diabetes treatments.
Related Concept Videos
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:17Oral Hypoglycemic Agents: Sulfonylureas
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...